To further confirm that the Wnt/β-catenin pathway is the pathway by which EZH2 promotes the proliferation of cervical cancer cells, XAV939, which is an inhibitor of Wnt/β-catenin that acts by stimulating β-catenin degradation via stabilizing axin, a component of the β-catenin destruction complex [31], and CHIR-99021, which is an inhibitor of GSK-3β that suppresses β-catenin degradation [32], were used to activate or block the Wnt/β-catenin pathway in EZH2-modified HeLa and SiHa cells. Here, EZH2 is linked to cervical carcinoma.